Wednesday, April 22, 2020
5:00 PM-6:15 PM
Barry J. Make, MD
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
University of Colorado School of Medicine
Co-Director, COPD Program
Director, Pulmonary Rehabilitation and Respiratory Care
Department of Medicine
National Jewish Health
Denver, Colorado
Richard H. Stanford, PharmD, MS
Vice President
Aesara
Adjunct Assistant Professor
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, North Carolina
Barbara P. Yawn, MD, MSc, FAAFP
Researcher
Adjunct Professor
Department of Family and Community Health
University of Minnesota
Rochester, Minnesota
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an independent educational grant from AstraZeneca.
Held in conjunction with AMCP eLearning Days.
This event will be hosted via Adobe Connect
please click here to
There is no registration fee for attending this virtual satellite symposium; however, participation is limited.
Target Audience
The educational design of this activity addresses the needs of managed care pharmacists, medical directors, and other health care professionals who help guide the treatment of patients with chronic obstructive pulmonary disease (COPD).
Program Description
The biopsychosocial and economic impact of COPD is substantial. Preventing exacerbations by optimizing the delivery of COPD care across the health care continuum is imperative to achieving the ultimate goal of improved patient outcomes. This engaging live webinar will assemble a multidisciplinary faculty panel consisting of a pulmonologist, a primary care physician, and a managed care pharmacist to provide expert insights and discuss best practices in the management of COPD—including exacerbation risk prevention and available and emerging therapeutic options—and how these factors may be used to shape managed care pharmacy decisions and future managed care paradigms. Pertinent patient case studies will also be utilized to provide examples of how recommended approaches to evidence and value-based care can be collaborative applied to health care systems.
Learning Objectives
Upon completion of this activity, the participant should be better able to:
- Characterize the clinical, economic, and health care utilization burdens of COPD exacerbations
- Discuss the latest evidence-based guidelines on COPD exacerbation prevention
- Describe the clinical profiles and potential cost offsets associated with newer maintenance treatment options for COPD
- Update benefit design strategies with new data and treatment modalities to optimize health care access and outcomes for patients with COPD
Agenda
- Participant Log-in and COPD Factoids
- Welcome and Faculty Introductions
- The Impact of COPD Exacerbations: A Patient Perspective
- The Impact of COPD Exacerbations: Resource Utilization and Cost
- Recommendations for COPD Exacerbation Prevention
- Managed Care Strategies to Reduce COPD Exacerbation Risks
- Question and Answer Session
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas. Global is accredited by the ACCME to provide continuing medical education for physicians.
*This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Global designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Credit (Universal Activity Number – 0530-9999-20-051-L01-P).
This is a knowledge-based activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete an online evaluation form. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.
Disclosure of Conflicts of Interest
Global requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Fee Information& Refund/Cancellation Policy
There is no fee for this educational activity.
Register Today!


18
2025
Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
Time: | 6:30 PM-8:30 PM PT |
Venue: | Marriott Marquis San Francisco, Yerba Buena 7 (Lower B2 Level) |
Location: | San Francisco, CA |
Faculty: | Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS; Professor Dave Singh MD, FERS, FBPhS; Jonathan M. Hand, MD |


18
2025
Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
Time: | 7:00 PM-8:30 PM PT |
Venue: | Live Stream |
Location: | Live Stream |
Faculty: | Jonathan M. Hand, MD; Professor Dave Singh MD, FERS, FBPhS; Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS |

19
2025
Turning the Tide on Eosinophilic Granulomatosis With Polyangiitis
New Targeted Strategies to Reduce Disease Burdens
Time: | 7:00 PM-8:30 PM PT |
Venue: | Live Stream |
Location: | Live Stream |
Faculty: | Michael E. Wechsler, MD, MMSc; Praveen Akuthota, MD; Anisha B. Dua, MD, MPH; Jason M. Springer, MD |

19
2025
Turning the Tide on Eosinophilic Granulomatosis With Polyangiitis
New Targeted Strategies to Reduce Disease Burdens
Time: | 6:30 PM-8:30 PM PT |
Venue: | Marriott Marquis San Francisco, Yerba Buena 7 (Lower B2 Level) |
Location: | San Francisco, CA |
Faculty: | Michael E. Wechsler, MD, MMSc; Praveen Akuthota, MD; Anisha B. Dua, MD, MPH; Jason M. Springer, MD |
